The Zacks Analyst Blog Highlights Berkshire Hathaway, Toyota Motor, McDonald's, Elite Pharmaceuticals and BK Technologies

28.08.25 10:36 Uhr

Werte in diesem Artikel
Aktien

425,65 EUR 2,45 EUR 0,58%

0,64 USD 0,00 USD 0,39%

16,48 EUR 0,26 EUR 1,63%

Indizes

PKT PKT

PKT PKT

47.619,4 PKT 1.849,9 PKT 4,04%

9.411,4 PKT 75,4 PKT 0,81%

18.081,7 PKT 100,0 PKT 0,56%

3.342,0 PKT -3,5 PKT -0,11%

6.715,8 PKT 0,4 PKT 0,01%

For Immediate ReleaseChicago, IL – August 28, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), Toyota Motor Corp. TM, McDonald's Corp. MCD, Elite Pharmaceuticals, Inc. ELTP and BK Technologies Corp. BKTI.Here are highlights from Wednesday’s Analyst Blog:Top Analyst Reports for Berkshire Hathaway, Toyota Motor and McDonald'sThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., Toyota Motor Corp. and McDonald's Corp., as well as two micro-cap stocks Elite Pharmaceuticals, Inc. and BK Technologies Corp. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Countdown to NVIDIA Earnings, PCE Report FridayToday's Featured Research ReportsBerkshire Hathaway’s shares have outperformed the Zacks Insurance - Property and Casualty industry over the year-to-date period (+9% vs. +7.8%). The company is one of the largest property and casualty insurance companies, with numerous diverse business activities. A strong cash position supports earnings-accretive bolt-on buyouts and is indicative of its financial flexibility.Continued insurance business growth fuels an increase in float, drives earnings and generates maximum return on equity. The non-insurance businesses have also been doing well in the last few years. The insurer has also started increasing its investment in Japan. A sturdy capital level provides further impetus.However, exposure to cat(astrophic) loss induces earnings volatility and also affects underwriting results. Huge capital expenditures remain a headwind. Also, it remains to be seen how the conglomerate behemoth fares when Greg Abel succeeds Warren Buffett as CEO of Berkshire.(You can read the full research report on Berkshire Hathaway here >>>)Shares of Toyota Motor have gained +0.8% over the year-to-date period against the Zacks Automotive - Foreign industry’s gain of +5%. The company’s sales are getting a boost from the surge in hybrid adoption. The RAV4 model, with hybrid variants that make up about half of Toyota’s sales, is America's top-selling SUV.Toyota Motor aims to lower hydrogen costs by promoting its use in commercial vehicles. It plans to sell its hydrogen-powered units externally, encouraging broader adoption beyond its own fleet. By increasing overall hydrogen demand, the company expects economies of scale to drive down production costs.However, Toyota expects its operating income for fiscal 2026 to decline year over year due to material prices, the impact of the forex rate and tariffs imposed by the U.S. government on vehicle and vehicle parts imports. Pretax profit is also expected to decline. Thus, the stock warrants a cautious stance.(You can read the full research report on Toyota Motor here >>>)McDonald's shares have outperformed the Zacks Retail - Restaurants industry over the year-to-date period (+10.1% vs. -2.3%). The company reported second-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate. Both the top and bottom lines increased year over year, driven by robust international comps, strong brand-led campaigns, loyalty expansion and solid menu innovation.The Accelerating the Arches strategy, supported by value platforms and unit expansion, continues to drive momentum. Management remains confident in its long-term growth trajectory, underpinned by unit expansion toward 50,000 restaurants by 2027.Earnings estimates for 2025 have increased in the past 30 days, depicting analysts' optimism regarding the stock’s growth potential. However, higher beef and labor costs in Europe, and soft traffic trends in the United States, pose concerns.(You can read the full research report on McDonald's here >>>)Shares of Elite Pharmaceuticals have outperformed the Zacks Medical - Drugs industry over the past year (+98.3% vs. -0.3%). This microcap company with a market capitalization of $586.35 million is capitalizing on the $3.5 billion U.S. ADHD market with its December 2024 launch of generic Lisdexamfetamine, quickly reaching 8–10% share while generic penetration lags peers, leaving room for growth.The first-quarter fiscal 2026 revenues surged 113.9% to $40.2 million, with gross margins expanding to 68% on the back of the shift to direct commercialization. Core Adderall IR/ER franchises provide stable cash flow as CNS and opioid analgesic launches diversify revenue.Strong liquidity ($21.7 million net cash, $67.1 million working capital) supports pipeline, M&A and global expansion. Risks include heavy reliance on Lisdexamfetamine amid pricing pressure, customer concentration, inventory build and offshore competition. The valuation reflects optimism around growth momentum, but also embeds risks tied to product concentration.(You can read the full research report on Elite Pharmaceuticals here >>>)BK Technologies’ shares have outperformed the Zacks Wireless Equipment industry over the past year (+225.3% vs. +30.1%). This microcap company with market capitalization of $255.79 million is driving growth through its BKR Series, notably the BKR 9000, which is gaining adoption across federal, state and local agencies due to competitive pricing, full P25 compliance and interoperability.Strong orders support revenue growth, with higher ASPs boosting margins. Gross margins expanded to 47.4% in Q2 2025, aided by mix shift and outsourced manufacturing, with guidance raised above 47%. SaaS platform BK ONE introduces high-margin recurring revenue streams, expanding TAM beyond hardware.BKTI has a debt-free balance sheet, supporting R&D and market expansion. Risks include customer concentration, software execution challenges, tariff exposure and delayed BKR 9500 launch. The valuation implies a discounted entry point, offering investors upside as BKTI scales high-margin products and SaaS, while managing execution risks.(You can read the full research report on BK Technologies here >>>)Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Zacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Toyota Motor Corporation (TM): Free Stock Analysis Report McDonald's Corporation (MCD): Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B): Free Stock Analysis Report Elite Pharmaceuticals Inc. (ELTP): Get Free Report BK TECHNOLOGIES, INC. (BKTI): Get Free ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Berkshire Hathaway und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Berkshire Hathaway

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Berkshire Hathaway

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Berkshire Hathaway Inc. B

Wer­bung

Analysen zu Berkshire Hathaway Inc. B

DatumRatingAnalyst
15.05.2025Berkshire Hathaway BuyUBS AG
05.05.2025Berkshire Hathaway BuyUBS AG
17.05.2012Berkshire Hathawa b kaufenDer Aktionär
08.05.2012Berkshire Hathawa b overweightBarclays Capital
04.10.2011Berkshire Hathawa b overweightBarclays Capital
DatumRatingAnalyst
15.05.2025Berkshire Hathaway BuyUBS AG
05.05.2025Berkshire Hathaway BuyUBS AG
17.05.2012Berkshire Hathawa b kaufenDer Aktionär
08.05.2012Berkshire Hathawa b overweightBarclays Capital
04.10.2011Berkshire Hathawa b overweightBarclays Capital
DatumRatingAnalyst
11.05.2010Berkshire Hathaway "equal-weight"Barclays Capital
14.04.2010Berkshire Hathaway "equal-weight"Barclays Capital
23.08.2007Berkshire Hathaway haltenWertpapier
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Berkshire Hathaway Inc. B nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen